R-VKORC1 Expression in Factor IX BHK Cells Increases the Extent of Factor IX Carboxylation but is Limited by Saturation of Another Carboxylation Component or by a Shift in the Rate-limiting Step

Overview

Journal Biochemistry

Specialty Biochemistry

Date 2006 Apr 26

PMID 16634640

Citations 17

Authors

Kevin W Hallgren

Wen Qian

Anna V Yakubenko

Kurt W Runge

Kathleen L Berkner

Affiliations

Soon will be listed here.

Abstract

Carboxylation of vitamin K-dependent (VKD) proteins is required for their activity and depends on reduced vitamin K generated by vitamin K oxidoreductase (VKOR) and a redox protein that regenerates VKOR activity. VKD protein carboxylation is inefficient in mammalian cells, and to understand why carboxylation becomes saturated, we developed an approach that directly measures the extent of intracellular VKD protein carboxylation. Analysis of factor IX (fIX)-expressing BHK cells indicated that slow egress of fIX from the endoplasmic reticulum and preferential secretion of the carboxylated form contribute to secreted fIX being more fully carboxylated. The analysis also revealed the first reported in vivo VKD protein turnover, which was 14-fold faster than that which occurs in vitro, suggesting facilitation of this process in vivo. r-VKORC1 expression increased the rate of fIX carboxylation and the extent of secreted carboxylated fIX approximately 2-fold, which shows that carboxylation is the rate-limiting step in fIX turnover and which was surprising because turnover in vitro is limited by release of carboxylated fIX. Interestingly, the increases were significantly smaller than the amount of VKOR overexpression (15-fold). However, when cell extracts were tested in single-turnover experiments in vitro, where redox protein is functionally substituted with dithiothreitol, VKOR overexpression increased the fIX carboxylation rate 14-fold, showing r-VKORC1 is functional for supporting fIX carboxylation. These data indicate that the effect of VKOR overexpression is limited in vivo, possibly because a carboxylation component like the redox protein becomes saturated or because another step is now rate-limiting. The studies illustrate the complexity of carboxylation and potential importance of component stoichiometry to overall efficiency.

Citing Articles

A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase.

Jin D, Chen X, Liu Y, Williams C, Pedersen L, Stafford D Nat Commun. 2023; 14(1):828.

PMID: 36788244 PMC: 9929328. DOI: 10.1038/s41467-023-36446-8.

Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact.

Chiasson M, Rollins N, Stephany J, Sitko K, Matreyek K, Verby M Elife. 2020; 9.

PMID: 32870157 PMC: 7462613. DOI: 10.7554/eLife.58026.

Exon 2 skipping eliminates γ-glutamyl carboxylase activity, indicating a partial splicing defect in a patient with vitamin K clotting factor deficiency.

Rishavy M, Hallgren K, Zhang H, Runge K, Berkner K J Thromb Haemost. 2019; 17(7):1053-1063.

PMID: 31009158 PMC: 7181818. DOI: 10.1111/jth.14456.

Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.

Rishavy M, Hallgren K, Wilson L, Singh S, Runge K, Berkner K Blood. 2018; 131(25):2826-2835.

PMID: 29592891 PMC: 6014353. DOI: 10.1182/blood-2017-09-804666.

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.

Czogalla K, Liphardt K, Honing K, Hornung V, Biswas A, Watzka M Blood Adv. 2018; 2(6):691-702.

PMID: 29581108 PMC: 5873226. DOI: 10.1182/bloodadvances.2017006775.

References

Hedner U . Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol. 2001; 38(4 Suppl 12):43-7. DOI: 10.1016/s0037-1963(01)90147-7. View

Hallgren K, Hommema E, McNally B, Berkner K . Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. Biochemistry. 2002; 41(50):15045-55. DOI: 10.1021/bi026016e. View

Sun Y, Jin D, Camire R, Stafford D . Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X. Blood. 2005; 106(12):3811-5. DOI: 10.1182/blood-2005-06-2495. View

Berkner K, Runge K . The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004; 2(12):2118-32. DOI: 10.1111/j.1538-7836.2004.00968.x. View

Whitlon D, Sadowski J, Suttie J . Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978; 17(8):1371-7. DOI: 10.1021/bi00601a003. View

Long 2nd D, Jaiswal A . NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact. 2001; 129(1-2):99-112. DOI: 10.1016/s0009-2797(00)00200-3. View

Rehemtulla A, Roth D, Wasley L, Kuliopulos A, WALSH C, Furie B . In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1993; 90(10):4611-5. PMC: 46562. DOI: 10.1073/pnas.90.10.4611. View

Lingenfelter S, Berkner K . Isolation of the human gamma-carboxylase and a gamma-carboxylase-associated protein from factor IX-expressing mammalian cells. Biochemistry. 1996; 35(25):8234-43. DOI: 10.1021/bi9523318. View

Kurachi K, Davie E . Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982; 79(21):6461-4. PMC: 347146. DOI: 10.1073/pnas.79.21.6461. View

10.

Hirsh J, Dalen J, Anderson D, Poller L, Bussey H, Ansell J . Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(1 Suppl):8S-21S. DOI: 10.1378/chest.119.1_suppl.8s. View

11.

Suttie J . Report of Workshop on expression of vitamin K-dependent proteins in bacterial and mammalian cells, Madison, Wisconsin, USA, April 1986. Thromb Res. 1986; 44(1):129-34. DOI: 10.1016/0049-3848(86)90189-1. View

12.

Price P, Kaneda Y . Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb Res. 1987; 46(1):121-31. DOI: 10.1016/0049-3848(87)90212-x. View

13.

Stenina O, Pudota B, McNally B, Hommema E, Berkner K . Tethered processivity of the vitamin K-dependent carboxylase: factor IX is efficiently modified in a mechanism which distinguishes Gla's from Glu's and which accounts for comprehensive carboxylation in vivo. Biochemistry. 2001; 40(34):10301-9. DOI: 10.1021/bi0107039. View

14.

Ross D, Siegel D . NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004; 382:115-44. DOI: 10.1016/S0076-6879(04)82008-1. View

15.

Souri M, Koseki-Kuno S, Iwata H, Kemkes-Matthes B, Ichinose A . A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency. Blood. 2005; 105(8):3149-54. DOI: 10.1182/blood-2004-06-2250. View

16.

Foster D, Holly R, Sprecher C, Walker K, Kumar A . Endoproteolytic processing of the human protein C precursor by the yeast Kex2 endopeptidase coexpressed in mammalian cells. Biochemistry. 1991; 30(2):367-72. DOI: 10.1021/bi00216a009. View

17.

Kaufman R, Wasley L, Furie B, Furie B, Shoemaker C . Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem. 1986; 261(21):9622-8. View

18.

Berkner K . Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. Methods Enzymol. 1993; 222:450-77. DOI: 10.1016/0076-6879(93)22029-f. View

19.

Malhotra O . Purification and characterization of dicoumarol-induced prothrombins. III. Alumina pH 4.6 atypical (2-Gla) variant. Thromb Res. 1979; 15(3-4):449-63. DOI: 10.1016/0049-3848(79)90151-8. View

20.

Roncaglioni M, Soute B, Vermeer C . Warfarin-induced accumulation of vitamin K-dependent proteins. Comparison between hepatic and non-hepatic tissues. Biochem Biophys Res Commun. 1983; 114(3):991-7. DOI: 10.1016/0006-291x(83)90658-7. View